In recent years, the anti-tumor effects of luteolin via the PI3K/AKT pathway have been well studied in a considerable number of tumor cells and animal models, including nasopharyngeal carcinoma cells,[45,51] choroidal melanoma cells,[52] chronic myeloid leukaemia cells,[53] cervical cancer cells,[54,55] lung cancer cells,[42,56] retinoblastoma,[57] glioblastoma,[58] osteosarcoma,[59] papillary thyroid cancer cells,[60] human tongue squamous carcinoma cells,[61] esophageal squamous carcinoma cells,[62] and colon cancer cells.[63]. This evidence concerns the gene AKT1 and colonic neoplasm.